Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
The INSPIRE-1 and INSPIRE-2 trials are Phase 3 studies assessing the efficacy and safety of tildrakizumab 100 mg (ILUMYA) in adults with active psoriatic arthritis (PsA)
Dilip Shanghvi to continue as the Executive Chairman of the Board
The company will also share results in two additional posters for deuruxolitinib
Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
Sun Pharma has reported consolidated financial results for the period ended September 30, 2021.
Moderate-to-severe plaque psoriasis affects about 35 per cent of patients. A key challenge is that many treatments stop working overtime and symptoms return
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
Subscribe To Our Newsletter & Stay Updated
